You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm saw durable consumables revenue in Q3, added five contracted instruments in the quarter, and brought 22 new instruments live in the US.
The company's system revenues were up 28 percent to $19.5 million and consumables revenues dropped 12 percent to $11.8 million.
The firm generated $68.7 million in revenues compared to $56.5 million in Q3 2019 and exceeded the consensus Wall Street estimate.
Product revenues increased 39 percent year over year to $93.3 million, while license and other revenues were down 56 percent to $4.9 million.
The firm submitted a new Emergency Use Authorization application to the FDA for a serology IgM/IgG test for SARS-CoV-2 after the agency revoked an earlier EUA for a similar test.
The health IT and precision oncology arm of Patrick Soon-Shiong's NantWorks conglomerate narrowed its quarterly net loss by 32 percent during the quarter.
The liquid biopsy's firm's net loss rose significantly year over year, but it beat the top line consensus Wall Street estimate, with total revenues of $74.6 million for the quarter.
Fluidigm tallied $39.9 million in revenues compared to $26.5 million a year ago, and well above analysts' consensus estimate of $32.5 million.
The Japanese diagnostics developer attributed the revenue decline to the impact of the ongoing SARS-CoV-2 pandemic on both domestic and international sales.
For the full year, the Franklin Lakes, New Jersey company saw a decline in revenues of 1 percent compared to 2019.